SYK
Stryker Corporation
NYSE · Healthcare · Medical - Devices · US
$302.89
−1.66%Year over year
Reported trailing growth
- Revenue
- +8.5%
- EBITDA
- +35.7%
- EBIT
- +5.2%
- EPS
- +27.2%
- Free cash flow
- +16.8%
- Operating cash flow
- +15.9%
Forward estimates
Based on analyst estimates
- Revenue
- +10.2%
- EBITDA
- +47.6%
- EPS
- +64.8%
Three-year CAGR
- Revenue
- +10.8%
- EBITDA
- +16.3%
- EBIT
- +9.4%
- Net income
- +11.2%
- EPS
- +10.9%
- Free cash flow
- +28.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026